Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Imaging Core Lab

Neither a doctor nor a teaching hospital

Research payments

$3,392,594

502 payments

Through program year 2025, Boston Imaging Core Lab is reported as receiving $3,392,594 in research payments, across 502 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $682,984 190
2024 Research $77,219 20
2023 Research $168,840 22
2022 Research $328,863 57
2021 Research $714,463 95
2020 Research $958,501 68
2019 Research $461,724 50

Breakdown

Who paid Research payments · program years 2019–2025
  1. Guerbet LLC $667,147 11 payments
  2. AstraZeneca UK Limited $562,891 49 payments
  3. AbbVie, Inc. $482,645 121 payments
  4. BeiGene, Ltd. $382,870 109 payments
  5. Hoffmann-La Roche Limited $382,280 50 payments
  6. Roche Products Limited $215,510 21 payments
  7. Acerta Pharma LLC $126,523 6 payments
  8. Novartis Pharmaceuticals Corporation $110,645 11 payments
  9. Eli Lilly and Company $102,820 1 payment
  10. Boehringer Ingelheim International GmbH $95,006 45 payments
Studies the money was for Research payments · program years 2019–2025
  1. Promise $667,147 11 payments
  2. Phase III Ipatasertib Plus Abirateron in McRpc 1St Line $359,200 29 payments
  3. A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma $331,210 87 payments
  4. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $266,029 9 payments
  5. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $246,150 22 payments
  6. Phase III Study in Adjuvant Therapy in Renal Cell Carcinoma Patients $215,510 21 payments
  7. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $201,527 13 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma $131,130 15 payments
  9. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) $119,790 17 payments
  10. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $105,720 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record